A treatment combining drugs from Amgen and AstraZeneca helped patients with an aggressive form of lung cancer live substantially longer in a major clinical trial, potentially opening a larger market for Amgen’s cancer medicine.
The combination reduced the risk of death by 58% compared with AstraZeneca’s Imfinzi alone, according to results released October 24. Median survival reached 21.1 months versus 12.7 months, an improvement of more than eight months.
The findings concern extensive-stage small-cell lung cancer, a fast-growing disease that has spread beyond a limited area. They could support using Amgen’s Imdelltra earlier in treatment, before the cancer progresses again.
What the Trial Found
The Phase 3 study, called DeLLphi-305, enrolled 563 patients whose cancer had not progressed after initial treatment with chemotherapy and Imfinzi. Patients then received either Imfinzi alone or Imfinzi combined with Imdelltra as maintenance treatment, which aims to keep the disease under control after initial therapy.
The planned interim analysis showed improvements in both survival and the length of time patients lived before their cancer worsened.
| Measure | Imdelltra Plus Imfinzi | Imfinzi Alone |
|---|---|---|
| Median overall survival | 21.1 months | 12.7 months |
| Estimated survival at one year | 79% | 53% |
| Median time before disease progression or death | 7.4 months | 1.9 months |
The companies presented the findings at the European Society for Medical Oncology congress in Madrid. Amgen first announced that the trial had succeeded in September; the weekend release supplied the detailed results.
The headline reduction in death risk describes the relative difference between the treatment groups during follow-up. It does not mean that 58% of patients were cured or that the result applies to every form of lung cancer.
Earlier Treatment Could Change the Commercial Opportunity
Imdelltra, also known as tarlatamab, already has a U.S. indication for adults with extensive-stage small-cell lung cancer whose disease progressed on or after platinum-based chemotherapy.
This trial tested an earlier opportunity: adding the drug while patients were still benefiting from their initial treatment.
That distinction matters because an aggressive cancer can progress quickly. Amgen says only about 40% of patients with extensive-stage small-cell lung cancer receive second-line treatment. Moving an effective therapy earlier could allow more patients to receive it before their condition deteriorates.
For Amgen, that creates a potential path to a broader eligible patient population. Regulatory approval, prescribing decisions and access to treatment would determine how much of that opportunity becomes revenue.
What It Means for Amgen and AstraZeneca
Amgen Could Reach More Patients
The investment case centers on expanding the role of an existing medicine. A successful earlier-use indication could increase the number of patients eligible for Imdelltra and make it more central to treatment.
Longer disease control could also support longer treatment duration. Investors should watch whether future company guidance translates these clinical results into changes in expected sales.
AstraZeneca Could Strengthen Imfinzi’s Position
The study also supports AstraZeneca’s business because Imfinzi remains part of the combination. A successful addition from another drugmaker can reinforce an established medicine’s position rather than displace it.
The commercial outcome could therefore benefit both companies, although their eventual gains would depend on adoption, pricing and reimbursement.
The Survival Benefit Comes With Trade-Offs
Adding another cancer medicine increased treatment-related side effects. Grade 3 or higher treatment-related adverse events occurred in 20.9% of patients receiving the combination, compared with 10.8% receiving Imfinzi alone.
Imdelltra also carries boxed warnings for cytokine release syndrome, a potentially dangerous immune reaction, and neurologic toxicity. Monitoring requirements and the ability of treatment centers to manage those risks are part of the practical adoption question.
Those considerations do not erase the survival improvement. They help explain why strong clinical results still require careful evaluation before a treatment becomes widely used.
The Next Decisions That Matter
The earlier maintenance use studied in DeLLphi-305 remains investigational. Amgen says it is moving to share the findings with regulators worldwide.
The next milestones are regulatory submissions and decisions, updates to treatment guidelines, and evidence that oncology practices can deliver the combination effectively. Insurance coverage and patient access would then influence how quickly use expands.
Investors should also distinguish a medical advance from an immediate stock-market payoff. A positive trial can strengthen a product’s prospects while leaving questions about launch timing, costs and the expectations already reflected in the share price.
For patients, the central finding is additional survival time in a difficult-to-treat disease. For Amgen and AstraZeneca, the opportunity is to turn that improvement into a broader role for their medicines.

